Chemoenzymatic synthesis of arabinomannan (AM) glycoconjugates as potential vaccines for tuberculosis.

Chemoenzymatic synthesis of arabinomannan (AM) glycoconjugates as potential vaccines for tuberculosis.

Publication date: Oct 15, 2020

Mycobacteria infection resulting in tuberculosis (TB) is one of the top ten leading causes of death worldwide in 2018, and lipoarabinomannan (LAM) has been confirmed to be the most important antigenic polysaccharide on the TB cell surface. In this study, a convenient synthetic method has been developed for synthesizing three branched oligosaccharides derived from LAM, in which a core building block was prepared by enzymatic hydrolysis in flow chemistry with excellent yield. After several steps of glycosylations, the obtained oligosaccharides were conjugated with recombinant human serum albumin (rHSA) and the ex-vivo ELISA tests were performed using serum obtained from several TB-infected patients, in order to evaluate the affinity of the glycoconjugate products for the human LAM-antibodies. The evaluation results are positive, especially compound 21 that exhibited excellent activity which could be considered as a lead compound for the future development of a new glycoconjugated vaccine against TB.

Concepts Keywords
Affinity TB
AM Branches of biology
Antibodies Medical specialties
Conjugated Microbiology
ELISA Tuberculosis
Glycosylations Lipoarabinomannan
Infection Carbohydrate chemistry
Lead Compound Carbohydrates
Mycobacteria Mycobacterium
Oligosaccharides Lam
Polysaccharide Oligosaccharide
Recombinant Glycoconjugate
Serum Antibodies
Serum Albumin
Tuberculosis
Vaccine

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH infection
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH causes of death
drug DRUGBANK Human Serum Albumin
disease MESH development

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *